ABO-503

About Abeona Therapeutics

Abeona Therapeutics is dedicated to delivering transformative cell and gene therapies for patients with severe rare diseases. The company has achieved a significant milestone with the commercial launch of ZEVASKYN® and maintains a diverse pipeline spanning preclinical to Phase 1/2 development, primarily targeting inherited retinal diseases and neurological conditions. Its strategy is supported by in-house manufacturing capabilities at The Elisa Linton Center for Rare Disease Therapies and key partnerships with Ultragenyx and Taysha Gene Therapies.

Therapeutic Areas